Sickle Cell (Acute Chest Syndrome)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

658 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp53

Immediate priorities

›Airway and oxygenation threats

›SpO2 <95% threshold for urgent intervention in known SCD

›SpO2 <90% despite supplemental O2 is critical — urgent exchange transfusion indication

›Target SpO2 >=95% with supplemental oxygen titration

›Signs of impending respiratory failure

›Increasing work of breathing with accessory muscle use

›Tachypnea >30 breaths/min despite O2 therapy

›Rising PaCO2 indicating ventilation failure

›If progressive hypoxemia not correcting with O2, escalate to high-flow nasal cannula

›BiPAP as bridge to exchange transfusion for selected patients

›Mechanical ventilation if respiratory failure is irreversible without transfusion

›Circulation and anemia threats

›Acute hemodynamic compromise

›SBP <90 mmHg or MAP <65 mmHg

›Tachycardia >120 bpm with pallor

›Acute anemia triggers

›Hb drop >1 g/dL below patient baseline

›Rapid decline in oxygen-carrying capacity in context of pulmonary shunt

›If hemodynamically unstable, initiate simple transfusion while arranging exchange

›10 mL/kg pRBCs for simple transfusion

›Target HbS% <30% for severe ACS via exchange transfusion

Escalation and alarm features

›Alarm features triggering ICU escalation

›Persistent SpO2 <90% on supplemental O2

›Indicates failure of simple supportive care

›Exchange transfusion indication — Class I NHLBI recommendation

›Multilobar pulmonary infiltrates with worsening trajectory

02History/hx58

Presenting symptoms

›Respiratory complaints

›Cough

›Productive versus dry character

›Onset relative to pain episode

›Chest pain

›Pleuritic quality — worsens with inspiration

›Back or chest wall pain suggesting rib infarction

›Dyspnea

›Exertional or at rest

›Rate of progression

›Wheezing

›Prior asthma or reactive airway disease

›Constitutional symptoms

›Fever

›Present in most children; adults often afebrile

›Night sweats and rigors

›Fatigue and malaise

›Pallor suggesting acute anemia

›Jaundice suggesting hemolysis

Temporal context

›Symptom onset and evolution

›Relationship to vaso-occlusive crisis

›ACS commonly develops within first 3-4 days of a VOC episode

›Night-time onset of VOC pain is independent risk factor for ACS progression

›Recent precipitants

›URI symptoms in days preceding admission

›Recent surgery especially abdominal or thoracic

03Physical Exam/exam45

Vital signs

›Hemodynamic and respiratory assessment

›Temperature

›Fever >38.5°C with leukocytosis predicts impending ACS

›Absence of fever does not exclude ACS — especially in adults

›Respiratory rate

›Tachypnea >20/min is a defining criterion for ACS

›>30/min indicates significant respiratory compromise

›SpO2 on room air and on supplemental O2

›<95% is threshold for intervention in SCD

›<90% despite supplemental O2 indicates exchange transfusion need

›Heart rate

›Tachycardia reflects pain, anemia, fever, or hypoxemia

›Disproportionate tachycardia may indicate hemodynamic compromise

Pulmonary exam

›Respiratory findings

›Breath sounds

›Crackles or rales suggest consolidation or pulmonary edema

›Decreased breath sounds unilaterally suggest pleural effusion

›Wheezing suggests bronchospasm or asthma comorbidity

›Percussion

›Dullness at bases indicates pleural effusion

›Focal dullness indicates lobar consolidation

›Work of breathing

›Accessory muscle use

›Intercostal or subcostal retractions

›Nasal flaring in pediatric patients

04Differential Diagnosis/ddx37

Life-threatening diagnoses

›Pulmonary emergencies requiring urgent action

›Pulmonary embolism — ICD-10 I26.99

›DVT risk elevated in SCD due to hypercoagulable state

›CT pulmonary angiography if clinical probability warrants

›ACS and PE can coexist

›Cardiac ischemia — ICD-10 I21.9

›Adults with SCD have elevated myocardial infarction risk

›ECG and troponin in adults with chest pain

›AHA/ACC 2021 chest pain guideline applies

›Pneumonia with sepsis — ICD-10 J18.9 / A41.9

›ACS clinically indistinguishable from bacterial pneumonia

›Empiric antibiotic coverage essential for both entities

›Multiorgan failure syndrome — ICD-10 R65.20

›ACS can trigger sequential organ failure

›Hepatic, renal, and neurologic dysfunction may coexist

Pulmonary mimics

›Conditions mimicking ACS

›Pneumonia — bacterial or atypical — ICD-10 J18.1

›S. pneumoniae, Mycoplasma, Chlamydia are common organisms in ACS

›Cannot be distinguished from ACS clinically; treat empirically for both

›Asthma exacerbation — ICD-10 J45.51

›Common comorbidity in SCD

›Peribronchial thickening and hyperinflation on CXR versus consolidation in ACS

›Pulmonary fat embolism — ICD-10 T79.1

›Major non-infectious ACS trigger — from bone marrow infarction during VOC

›No specific radiographic distinguishing feature from infectious ACS

›Atelectasis — ICD-10 J98.11

05Laboratory Tests/lt62

Hematologic studies

›Complete blood count with differential

›Hemoglobin compared to patient baseline

›Drop >1 g/dL below baseline indicates active hemolysis or sequestration

›Severe anemia (Hb <60 g/L) may trigger transfusion

›White cell count

›Leukocytosis at presentation predicts higher ACS severity

›Baseline WBC elevation common in SCD — compare to known baseline

›Platelet count

›Thrombocytopenia may suggest concurrent VOC severity

›Platelet activation contributes to ACS pathogenesis

›Reticulocyte count

›Reticulocyte percentage and absolute count

›Aplastic crisis produces reticulocytopenia — parvovirus B19 consideration

›High reticulocyte count confirms active hemolysis

›Peripheral blood smear

›Morphology for sickle cells, target cells, Howell-Jolly bodies

›Howell-Jolly bodies confirm functional asplenia

›Quantitative HbS assessment guides exchange transfusion target

Chemistry and inflammatory markers

›Metabolic panel

›Creatinine and BUN for renal function

›Baseline creatinine often low in SCD — even small rises significant

›Elevated creatinine signals renal involvement in MSOF

›Liver function tests

›Total and direct bilirubin elevated in active hemolysis

›Transaminase elevation suggests hepatic sequestration or ischemia

›LDH

06Diagnostic Tests/dt68

Scoring Systems

›ACS diagnostic criteria (NHLBI 2014 definition)

›New radiographic pulmonary infiltrate plus at least two of the following

›Fever >38.5°C

›Pleuritic chest pain

›Cough or tachypnea

›Hypoxemia (SpO2 <95% or decrease from baseline)

›Clinical note: initial CXR may be negative — repeat at 12-24 hours if ACS clinically suspected

›Absence of radiographic infiltrate does not exclude early ACS

›JAMA 2022: ACS diagnosis requires both clinical and radiographic components

›Severity stratification

›Mild ACS

›SpO2 >=95% on room air

›No more than one lobe affected

›No MSOF features

›Moderate ACS

›SpO2 90-94% or requires supplemental O2

›Multi-lobar involvement

›Pain requiring IV opioids

›Severe ACS

›SpO2 <90% on supplemental O2

›Rapidly progressive respiratory failure

›MSOF features present

›Exchange transfusion indicated

MRI

›MRI chest and bone marrow

›Indications

›Suspected pulmonary fat embolism from bone marrow necrosis

›Evaluation of rib and sternal infarction

›Not first-line in acute ACS — CXR and CT are preferred initially

›MRI findings in ACS

›Bone marrow signal abnormalities on STIR sequences indicating infarction

›Fat emboli may appear as diffuse micronodular pulmonary opacities

›MRI brain

›Indicated if neurologic symptoms present — stroke coexists in up to 10% of severe ACS cases

›DWI sequence is most sensitive for acute ischemic stroke

›MRA for large vessel involvement

›CT chest

›Indications

›Equivocal CXR with high clinical suspicion

›Differentiation of ACS from PE or other diagnoses

›Characterization of extent of pulmonary involvement

›CT pulmonary angiography

›Preferred modality when PE is suspected concurrently with ACS

›Sensitivity for PE approximately 83-95%

›Can simultaneously characterize consolidation pattern

›CT findings in ACS

›Consolidation: lower lobe predominant early

›Ground-glass opacities in fat embolism pattern

›Bilateral perihilar infiltrates in severe disease

›Pleural effusions common — unilateral or bilateral

›CT brain

›Indication: altered mental status or focal neurologic findings

›Stroke and ACS can coexist in the same admission

›Non-contrast CT first for hemorrhage exclusion; MRI for ischemic stroke

Ultrasound

›Point-of-care ultrasound

›Lung ultrasound

›B-lines indicate interstitial edema or consolidation

›Subpleural consolidations visible as hepatization pattern

›Absence of lung sliding may indicate pneumothorax — important if under positive pressure

›Pleural assessment

›Pleural effusion size and character

›Guidance for thoracentesis if large symptomatic effusion

›Cardiac ultrasound

›Right ventricular strain pattern suggests acute cor pulmonale or PE

›Pulmonary hypertension screening — TRV >2.5 m/s warrants formal echocardiography

›Left ventricular function for guiding fluid management

›Abdominal ultrasound

›Splenic enlargement with acute Hb drop suggests sequestration

›Hepatic size and echogenicity for hepatic sequestration

07Disposition/dispo41

Admission indications

›Admission criteria

›All patients meeting ACS diagnostic criteria require hospital admission

›ACS is a life-threatening complication — outpatient management not appropriate

›NHLBI Expert Panel 2014 — Class I recommendation

›Standard ward admission for mild ACS

›SpO2 >=95% on room air or low-flow O2 nasal cannula

›Unilateral or single-lobe involvement

›Responding to initial management within first hours

›Step-down or intermediate care for moderate ACS

›O2 requirement but SpO2 maintainable >=92%

›Multi-lobar disease without MSOF features

›Requires closer respiratory monitoring than standard ward

ICU indications

›ICU admission criteria

›SpO2 <90% on supplemental O2

›Indicates failure of simple measures

›Exchange transfusion typically being initiated

›Need for exchange transfusion

›Requires continuous monitoring during procedure

›Hemodynamic instability risk during apheresis

›Rapidly progressive respiratory failure

›Rising O2 requirement over hours

›HFNC or positive pressure ventilation initiated

›Multilobar bilateral disease with worsening trend

›Nearly one-third of pediatric ACS cases require ICU-level care

›Signs of MSOF

›Neurologic, renal, or hepatic co-involvement

08Treatment/t112

Supplemental oxygen

›Oxygen therapy

›Nasal cannula titrated to SpO2 >=95%

›Start at 2-4 L/min and adjust to target

›Monitor continuously during titration

›High-flow nasal cannula for moderate-severe ACS

›Flow rates 20-60 L/min with FiO2 titrated to SpO2 >=95%

›Reduces work of breathing and improves alveolar recruitment

›Non-invasive positive pressure ventilation

›BiPAP as bridge while exchange transfusion is being arranged

›CPAP 5-10 cmH2O; IPAP 12-20 cmH2O as starting point

›Contraindicated if unable to protect airway or high emesis risk

›Mechanical ventilation

›Reserve for respiratory failure not responding to exchange transfusion

›Lung-protective strategy: tidal volume 6 mL/kg ideal body weight

›PEEP 5-8 cmH2O initially; titrate to oxygenation response

Incentive spirometry

›Respiratory therapy

›Incentive spirometry every 2 hours while awake

›Reduces atelectasis progression during VOC hospitalization

›Lancet 2016: inadequate spirometry during VOC is a modifiable ACS risk factor

›Initiate at VOC admission before ACS develops

›Target maximum inspiratory volume sustained for 3-5 seconds

Transfusion therapy

›Simple transfusion

›Indications for simple transfusion

›Hb drop >1 g/dL below baseline during ACS

›Hb <60-70 g/L in context of worsening oxygenation

›Used in mild-moderate ACS without rapid progression

›Simple transfusion protocol

›10 mL/kg pRBCs over 3-4 hours

›Phenotypically matched blood preferred (C, E, Kell, Duffy, Kidd)

›Monitor for transfusion-related acute lung injury (TRALI) and volume overload

›Do not transfuse if Hb >100 g/L — hyperviscosity risk

›Exchange transfusion

›Indications for exchange transfusion

›SpO2 <90% on supplemental O2

›Severe or rapidly progressive ACS

›Hb decline despite simple transfusion

›Multilobar disease with worsening trajectory

›NHLBI 2014 — Class I recommendation for severe ACS

›Exchange transfusion targets

›HbS% <30% post-exchange

›Target Hb 80-100 g/L post-exchange

›Hematology guidance required for procedural parameters

›Manual versus automated apheresis

›Automated red cell exchange preferred when available

›Manual exchange as alternative when apheresis not available

›Cochrane 2020: limited RCT evidence but consensus strongly favors exchange in severe ACS

Empiric antibiotic therapy

›Antibiotic regimen

›Dual coverage for typical and atypical organisms

›IV cephalosporin plus oral macrolide — NHLBI 2014 standard recommendation

›Ceftriaxone 1-2 g IV every 24 hours for adults

›Covers S. pneumoniae, including functional asplenic risk

›Reduce to 50 mg/kg every 24 hours for pediatric patients (max 2 g)

›Azithromycin 500 mg orally once daily for adults

›Covers Mycoplasma pneumoniae and Chlamydophila pneumoniae

›Pediatric dosing: 10 mg/kg orally once daily (max 500 mg)

›Duration of antibiotic therapy

›Typically 5-7 days total course

›Extend if blood cultures positive or clinical response delayed

›Antibiotic modification

›Penicillin allergy: use azithromycin monotherapy or fluoroquinolone-based regimen

›Add coverage for Gram-negative organisms if post-splenectomy or immunocompromised

Analgesia

›Pain management

›Opioid analgesics for ACS-related chest pain

›Titrate to achieve adequate pain relief

›Avoid sedation-causing doses — hypoventilation worsens atelectasis

›Morphine IV 0.05-0.1 mg/kg every 2-4 hours prn for adults

›PCA delivery preferred for continuous pain assessment and patient control

›Reduces over-sedation risk versus nurse-administered boluses

›Monitor respiratory rate and SpO2 closely with opioid use

›Combine with non-opioid adjuncts to minimize opioid burden

›Non-opioid adjuncts

›Ketorolac 15-30 mg IV every 6 hours for adults — short-term use

›Avoid with renal impairment or known nephropathy

›Acetaminophen 1000 mg orally every 6-8 hours

›Avoid meperidine — seizure risk in SCD patients

Bronchodilators

›Inhaled bronchodilator therapy

›Inhaled beta-agonist for bronchospasm

›Salbutamol (albuterol) 2.5-5 mg nebulized every 4-6 hours

›Indicated when wheezing or reactive airway component present

›Reduces airway resistance and promotes alveolar ventilation

›Ipratropium bromide 0.5 mg nebulized can be added for severe bronchospasm

›Combined with salbutamol for acute asthma-like presentation

›Ipratropium-salbutamol combination

›For patients with known asthma and ACS

›ACEP Level C — bronchodilator use in ACS with reactive airway component

Fluid management

›IV fluid therapy

›Target euvolemia

›D5 0.45% NaCl at maintenance rate as standard

›Avoid hypotonic fluids in severe anemia — risk of hemolysis

›Monitor urine output 0.5-1 mL/kg/hour

›Avoid overhydration

›Hyperhydration worsens pulmonary edema in ACS — Cochrane 2020

›Total daily fluid goal approximately 1-1.5x maintenance in adults

›Avoid dehydration

›Dehydration promotes sickling and worsens VOC and ACS

Corticosteroids

›Steroid use — caution required

›Dexamethasone

›Short-term benefit shown in some pediatric studies (faster resolution of fever, O2 need)

›Associated with rebound pain and rehospitalization — European Journal of Haematology 2026

›Not routinely recommended — use only in severe asthma component

›If used: dexamethasone 0.3 mg/kg IV x1 dose maximum

›Risk-benefit decision requires hematology input

›Rebound crisis risk substantial especially in HbSS

Disease-modifying therapy

›Hydroxyurea

›Primary preventive agent — not for acute rescue

›Reduces ACS incidence: RR 0.42 versus standard care

›Mechanism: increases HbF, reduces HbS polymerization and adhesion

›Initiation or optimization post-ACS

›NHLBI 2014: initiate after first ACS episode if not already on therapy

›Starting dose 15 mg/kg/day orally; titrate to maximum tolerated dose

›Maximum 35 mg/kg/day

›Monitor CBC every 4-8 weeks during titration

09Special Populations/sp62

Pregnancy

›Pregnancy-specific considerations

›Increased ACS risk in pregnancy

›Physiologic anemia of pregnancy worsens underlying SCD anemia

›Diaphragmatic elevation from gravid uterus reduces FRC and promotes atelectasis

›Vaso-occlusive crises more frequent in second and third trimesters

›Antibiotic safety in pregnancy

›Ceftriaxone is safe in pregnancy — category B

›Azithromycin is generally safe in pregnancy — preferred macrolide

›Avoid fluoroquinolones — category C with cartilage risk concerns

›Transfusion in pregnancy

›Simple and exchange transfusion both indicated in severe ACS regardless of gestational age

›Phenotypically matched blood is critical — alloimmunization affects future obstetric care

›Hematology and maternal-fetal medicine co-management required

›Oxygen targets

›Maintain SpO2 >=95% — fetal oxygenation dependent on maternal saturation

›Left lateral positioning in third trimester to optimize venous return

›Fetal monitoring

›Continuous fetal heart rate monitoring in second and third trimester

›Obstetrics consultation for all ACS cases in pregnancy

›Hydroxyurea

›Contraindicated in pregnancy — teratogenic

›Discontinue before conception or at pregnancy recognition

Geriatric

›Geriatric-specific considerations

›Cumulative end-organ damage in older SCD patients

›Chronic lung disease from repeated ACS episodes reduces pulmonary reserve

›Pulmonary hypertension prevalence increases with age — TRV >2.5 m/s in up to 30% of adults

10Background/b63

Epidemiology

›Disease burden

›Prevalence and incidence of ACS

›Approximately 50% of SCD patients will experience at least one ACS episode during their lifetime

›Second most common reason for hospitalization in SCD after VOC

›Leading cause of death in sickle cell disease — JAMA 2022

›Demographics

›Peak incidence in children aged 2-4 years

›Adult disease has higher severity and mortality

›HbSS and HbSβ0-thalassemia have highest lifetime ACS risk

›Incidence relative to VOC

›Approximately 15.7% of VOC hospitalizations progress to ACS — Scientific Reports 2024

›Triggers include infection, fat embolism, hypoventilation, and dehydration

›Outcomes

›Up to 20% of adult ACS patients progress to respiratory failure requiring mechanical ventilation

›Cumulative ACS episodes cause progressive lung function decline

›Mortality from ACS: approximately 1-3% per episode; higher in adults with MSOF

Pathophysiology

›Mechanisms of ACS

›Primary pathways

›Vascular occlusion by sickled erythrocytes in pulmonary vasculature

›Deoxygenation promotes HbS polymerization — exponential sickling below pO2 of 40 mmHg

›Adhesion molecules (P-selectin, VCAM-1) promote erythrocyte-endothelial binding

›Pulmonary fat embolism

›Bone marrow necrosis during VOC releases fat and marrow emboli

›Fat emboli occlude pulmonary capillaries — major non-infectious ACS cause

›Infection and airway inflammation

›Bacterial pneumonia in functionally asplenic host

›Viral triggers cause airway inflammation and atelectasis

›Atypical organisms (Mycoplasma, Chlamydophila) common in all ages

›Amplification loop

›Pulmonary hypoxia worsens sickling in pulmonary vasculature

›Creates self-perpetuating cycle of hypoxia and vasoocclusion

›Hemolysis releases free hemoglobin scavenging nitric oxide

›NO depletion promotes vasoconstriction and platelet activation

›Increases pulmonary vascular resistance

›Role of asthma comorbidity

›Reactive airway disease causes bronchoconstriction and air trapping

›Air trapping creates regional hypoxia promoting intrapulmonary sickling

›ACS incidence significantly higher in SCD patients with asthma

Therapeutic Considerations

›Evidence base for key interventions

›Exchange transfusion evidence

›Rapidly reduces HbS% and improves oxygen-carrying capacity

›Cochrane 2020: no high-quality RCTs; evidence from observational data and expert consensus

›NHLBI 2014: Class I recommendation for severe ACS despite limited RCT evidence

›Reduces pulmonary sickling by diluting HbS concentration

›Hydroxyurea evidence

›Reduces ACS frequency: RR 0.42 versus placebo in MSH trial

›Increases HbF proportion — fetal hemoglobin inhibits HbS polymerization

›Long-term use reduces end-organ damage and mortality

›European Journal of Haematology 2026: network meta-analysis supports hydroxyurea for prevention

›Antibiotic evidence

›Combination cephalosporin plus macrolide — NHLBI 2014 standard

›Atypical organisms identified in 17-29% of ACS cases microbiologically

›Viral triggers identified in 29% of pediatric series

›Corticosteroid controversy

›Dexamethasone reduces inpatient O2 requirement and readmission within episode

›Increases risk of rebound pain crisis and rehospitalization

›No longer routinely recommended by most guidelines

›Emerging therapies

›Voxelotor (GBT440): inhibits HbS polymerization — FDA approved for SCD

›Not yet established as ACS-specific acute treatment

›Crizanlizumab: anti-P-selectin monoclonal antibody — reduces VOC frequency

›May reduce ACS by reducing VOC burden

›Gene therapy: curative potential; not available in acute setting

11Patient Discharge Instructions/pdi26

copy discharge instructions

›Discharge instructions for Sickle Cell Acute Chest Syndrome

›What happened

›You were treated for acute chest syndrome (ACS), a serious lung complication of sickle cell disease

›ACS occurs when sickle-shaped red blood cells block blood flow in the lungs and can be worsened by infection

›You may still feel some chest pain or shortness of breath as you recover over the coming days to weeks

›Medications to take at home

›Complete the full course of antibiotics as prescribed — do not stop early even if you feel better

›Take all pain medications as directed — avoid letting pain get severe before taking them

›Continue hydroxyurea as prescribed — do not skip doses

›If you were newly started on hydroxyurea, follow up with your hematologist for dose adjustments

›Activity and breathing

›Use your incentive spirometer (breathing device) at home every 2 hours while awake

›Take 10 deep breaths with the spirometer each time and hold each breath for 3-5 seconds

›Gradually increase activity as tolerated — rest when short of breath

›Avoid smoking and secondhand smoke — worsens lung recovery

›Follow-up appointments

›Hematology appointment within 1-2 weeks of discharge — do not miss this visit

›Lung function testing may be arranged after recovery to assess any permanent damage

›Confirm all vaccinations are up to date at your follow-up visit

›Return to the emergency department immediately if

›Fever >=38.5°C (101.3°F)

›New or worsening chest pain, cough, or shortness of breath

›Difficulty breathing at rest or with minimal activity

›Increasing fatigue, severe pallor, or yellowing of the eyes

›Confusion, severe headache, weakness, or difficulty speaking

›Pain that is not controlled with your home medications

12References/r31

Guidelines and key sources

›Primary guidelines

›NHLBI Expert Panel Report 2014 — Evidence-Based Management of Sickle Cell Disease

›Definitive guideline for transfusion thresholds, antibiotic choice, and ICU criteria

›Class I recommendation: exchange transfusion for severe ACS

›JAMA 2022 — Kavanagh PL et al. Sickle Cell Disease: A Review

›Comprehensive review including ACS definition, epidemiology, and management

›Annals of Intensive Care 2025 — Mekontso Dessap A et al.

›Guidelines for management of emergencies and critical illness in SCD

›Pediatrics 2024 — Yates AM et al.

›Health supervision for children and adolescents with SCD; ACS monitoring

›Supporting studies

›American Journal of Emergency Medicine 2022 — Koehl JL et al.

›High risk and low prevalence disease review: ACS in SCD emergency management

›Scientific Reports 2024 — Alghamdi FA et al.

›Risk factors for ACS among children with SCA hospitalized for VOC

›Scientific Reports 2020 — Alkindi S et al.

›Predictors of impending ACS in SCA — leukocytosis, CRP, bilateral effusions

›Cochrane Database 2020 — Dolatkhah R, Dastgiri S

›Blood transfusions for treating ACS — systematic review

›European Journal of Haematology 2026 — Alsabri M et al.

›Network meta-analysis: prevention and management of ACS without automated exchange

›Lancet 2016 — DeBaun MR, Strunk RC

›Intersection of asthma and ACS in children with SCA

›PloS One 2025 — Conde M et al.

›Early risk factors for ACS in sickle cell anemia — pediatric study

›European Respiratory Review 2024 — Ahmed B et al.

›Respiratory management of ACS in children with SCD

Learn More: Sickle Cell (Acute Chest Syndrome)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.